Emerging Company Profile: Turning to gene therapy after its dry eye drug didn’t work out, Ocugen hopes to overcome financial challenges to bring a gene therapy into the clinic for numerous mutations of RP.

Reverse merger takes Histogen public as it seeks mid-stage data for male pattern baldness by end of 2020. AstraZeneca continues divestiture spree, sending five mature hypertension drugs to Atnahs.

The sheer size of the stress urinary incontinence market and the potential for future growth have attracted the attention of a number of emerging companies. Although investor interest has waxed and waned over the years, it appears to be heating up once again. This renewed interest is being driven in part by the push to develop efffective nonsurgical treatments that will appeal to an increasingly health-savvy patient population.

Noteworthy news from medtech start-ups. In this issue: New Scaffolds for Tissue Engineering, with brief profiles of BioCeramic Therapeutics Ltd., Histogen Inc., Humacyte Inc., and Tissue Regenix. (Adapted from "Scaffolds in Tissue Engineering," START-UP, February 2008.)